This page is part of the FHIR Specification (v4.1.0: Release 4B Ballot #1). The current version which supercedes this version is 5.0.0.  For a full list of available versions, see the Directory of published versions  . Page versions: R5 R4B R4 R3
. Page versions: R5 R4B R4 R3
| Pharmacy Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: Device, Encounter, Patient, Practitioner, RelatedPerson | 
This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile MedicationAdministration.
Generated Narrative
status: completed
code: Myleran 2mg tablet, film coated
effective: 16 Jan. 2015, 8:03:00 am --> 16 Jan. 2015, 12:03:00 pm
| - | Text | Route | Dose | 
| * | 6 mg PO daily for remission induction; adjust dosage to white blood cell (WBC) count. With hold treatment if WBC is less than 15,000/µL; resume when WBC is greater than 50,000/µL | Oral route (qualifier value) | 6 mg | 
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.